STOCK COMMENTS / EPS CHANGES

Apple ( AAPL) numbers were cut at UBS. Shares are now seen reaching $650. Estimates were also lowered on iPhone ASPs, UBS said. Buy rating.

Citigroup ( C) numbers were cut at Sterne Agee. Shares of Citigroup are now seen reaching $48. Estimates were also lowered on management's sober outlook for legacy mortgage-related costs, Citi said. Buy rating.

Deckers ( DECK) numbers were cut at Canaccord Genuity. Shares are now seen reaching $35. Estimates were also lowered as challenged holiday bodes ill for 2013 orders, Canaccord Genuity said. Hold rating.

Facebook ( FB) estimates, target were raised at Topeka. Shares are now seen reaching $40. Estimates were also increased, given higher expected advertising growth, Topeka said. Buy rating.

First Republic Bank ( FRC) numbers were raised at Jefferies. Shares are now seen reaching $42. Estimates also raised on mortgage banking performance, Jefferies said. Buy rating.

Johnson Controls ( JCI) price target was raised at Jefferies. Shares are now seen reaching $31. Leverage the HVAC cycle, Jefferies said. Hold rating.

Life Technologies ( LIFE) price target was raised at Oppenheimer. Shares are now seen reaching $67. Strategic more likely than LBO, Oppenheimer said. Outperform rating.

Lorillard ( LO) numbers were lowered at Jefferies. Shares are now seen reaching $43. Update following stock split, Jefferies said. Buy rating.

Parker Hannifin ( PH) numbers were raised at BMO Capital Markets. Shares are now seen reaching $108. Estimates were also increased as FY2Q better than lowered expectations, BMO Capital Markets said. Outperform rating.

Sandisk ( SNDK) numbers were raised at Jefferies. Shares are now seen reaching $59. Estimates were also raised on gross margin upside, Jefferies said. Buy rating.

State Street ( STT) numbers were raised at Citigroup. Shares are now seen reaching $61. Estimates were also increased ahead of analyst day and CCAR results, Citigroup said. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback